Tribenzor

Tribenzor is a brand name of amlodipine/hydrochlorothiazide/olmesartan, approved by the FDA in the following formulation(s):

TRIBENZOR (amlodipine besylate; hydrochlorothiazide; olmesartan medoxomil - tablet; oral)

• 
  Manufacturer: DAIICHI SANKYO
  
  Approval date: July 23, 2010
  
  Strength(s): EQ 10MG BASE;12.5MG;40MG, EQ 10MG BASE;25MG;40MG ^[RLD], EQ 5MG BASE;12.5MG;20MG, EQ 5MG BASE;12.5MG;40MG, EQ 5MG BASE;25MG;40MG
  

Has a generic version of Tribenzor been approved?

No. There is currently no therapeutically equivalent version of Tribenzor available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Tribenzor. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
  Patent 5,616,599
  Issued: April 1, 1997
  Inventor(s): Yanagisawa; Hiroaki & Fujimoto; Koichi & Amemiya; Yoshiya & Shimoji; Yasuo & Kanazaki; Takuro & Koike; Hiroyuki & Sada; Toshio
  Assignee(s): Sankyo Company, Limited
  Compounds of the following formula (I) or the formula (I).sub.p : ##STR1## wherein R.sup.1 is alkyl or alkenyl; R.sup.2 and R.sup.3 are hydrogen, alkyl, alkenyl, cycloalkyl, aralkyl, aryl, or aryl fused to cycloalkyl; R.sup.4 is hydrogen, alkyl, alkanoyl, alkenoyl, arylcarbonyl, alkoxycarbonyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrothienyl, tetrahydrofuryl, a group of formula --SiR.sup.a R.sup.b R.sup.c, in which R.sup.a, R.sup.b and R.sup.c are alkyl or aryl, alkoxymethyl, (alkoxyalkoxy)methyl, haloalkoxymethyl, aralkyl, aryl or alkanoyloxymethoxycarbonyl; R.sup.5 is carboxy or --CONR.sup.8 R.sup.9, wherein R.sup.8 and R.sup.9 hydrogens or alkyl, or R.sup.8 and R.sup.9 together form alkylene; R.sup.6 is hydrogen, alkyl, alkoxy or halogen; R.sup.7 is carboxy or tetrazol-5-yl; R.sub.p.sup.1 is hydrogen, alkyl, cycloalkyl or alkanoyl; R.sub.p.sup.2 is a single bond, alkylene or alkylidene; R.sub.p.sup.3 and R.sub.p.sup.4 are each hydrogen or alkyl; R.sub.p.sup.6 is carboxy or tetrazol-5-yl; and X.sub.p is oxygen or sulfur; and pharmaceutically acceptable salts and esters thereof. The compounds are AII receptor antagonists and thus have hypotensive activity and can be used for the treatment and prophylaxis of hypertension. The compounds may be prepared by reacting a biphenylmethyl compound with an imidazole compound.
  
  Patent expiration dates:
  
  
  • April 25, 2016
    
    ✓ 
    Patent use: TREATMENT OF HYPERTENSION
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • October 25, 2016
    
    ✓ 
    Pediatric exclusivity
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • July 23, 2013 - NEW COMBINATION
  
  

See also...

• Tribenzor Consumer Information (Drugs.com)
• Tribenzor Consumer Information (Wolters Kluwer)
• Tribenzor Consumer Information (Cerner Multum)
• Tribenzor Advanced Consumer Information (Micromedex)
• Amlodipine/Olmesartan/Hydrochlorothiazide Consumer Information (Wolters Kluwer)
• Amlodipine, hydrochlorothiazide, and olmesartan Consumer Information (Cerner Multum)
• Olmesartan, amlodipine, and hydrochlorothiazide Advanced Consumer Information (Micromedex)